This phase 3 study compares BRAF-targeted therapy (dabrafenib-trametinib) to TKI therapy (cabozantinib) in patients with disease progression after standard treatments
This clinical trial is exploring whether PARP inhibitors will improve outcomes for patients with early-stage pancreas cancer that has BRCA or PALB2 mutations
This phase 3 clinical trial is testing a new treatment approach for patients with treatment-refractory locally-advanced or metastatic urothelial cancer